NightHawk lays off 14% of R&D work­force, piv­ots to fo­cus on CD­MO Scor­pius Bio­man­u­fac­tur­ing

NightHawk Bio­sciences laid off 14% of its work­force in R&D in or­der to fo­cus on its con­tract de­vel­op­ment and man­u­fac­tur­ing or­ga­ni­za­tion (CD­MO), just a lit­tle over a month af­ter the com­pa­ny’s CEO said it was con­tin­u­ing its R&D ac­tiv­i­ties and was “high­ly en­cour­aged” by pre­clin­i­cal da­ta.

The de­ci­sion to lay off 13 em­ploy­ees was made af­ter the board of di­rec­tors ap­proved a “re­fo­cus and re­struc­tur­ing plan” to axe “non-core as­sets” and re­duce op­er­at­ing costs, as NightHawk builds up its CD­MO Scor­pius Bio­man­u­fac­tur­ing, the com­pa­ny said in SEC fil­ings Tues­day. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.